Amy Rothberg

Prof. Dr. Amy Rothberg

University of Michigan Ann Arbor

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2021 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
MRMatthew C. Riddle
Matthew C. Riddle
WCWilliam T. Cefalu
William T. Cefalu
PEPhilip H. Evans
Philip H. Evans
HGHertzel C. Gerstein
Hertzel C. Gerstein
MNMichael A. Nauck
Michael A. Nauck
DTDouglas Twenefour
Douglas Twenefour
Improvement of glucose levels into the normal range can occur in some people living with diabetes, either spontaneously or after medical interventions, and in some cases can persist after withdrawal of glucose-lowering pharmacotherapy. Such sustained improvement may now be occurring more often due to newer forms of treatment. However, terminology for describing this process and objective measures for defining it are not well established, and the long-term risks versus benefits of its attainment are not well understood. To update prior discussions of this issue, an international expert group was convened by the American Diabetes Association to propose nomenclature and principles for data collection and analysis, with the goal of establishing a base of information to support future clinical guidance. This group proposed “remission” as the most appropriate descriptive term, and HbA1c <6.5% (48 mmol/mol) measured at least 3 months after cessation of glucose-lowering pharmacotherapy as the usual diagnostic criterion. The group also made suggestions for active observation of individuals experiencing a remission and discussed further questions and unmet needs regarding predictors and outcomes of remission.

1 December 2016 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
BCBrian C. Callaghan
Brian C. Callaghan
RXRong Xia
Rong Xia
EREvan Reynolds
Evan Reynolds
MBMousumi Banerjee
Mousumi Banerjee
ARAmy Rothberg
Amy Rothberg
EFEva L. Feldman
Eva L. Feldman
Polyneuropathy is a prevalent, disabling condition affecting 2% to 7% of the population1,2; however, a definitive cause is lacking in 30% of patients.3,4 The most common etiologic condition is diabetes, with a similar prevalence in patients with types 1 and 2 diabetes.5-9 In patients with type 1 diabetes, enhanced glucose control reduces the incidence of polyneuropathy substantially, but in those with type 2 diabetes, the effect does not reach statistical significance.10 Therefore, factors other than glucose control are likely to be involved in the development of type 2 diabetic polyneuropathy.11 These same factors may also explain why patients are diagnosed with idiopathic polyneuropathy. Components of metabolic syndrome are potential aspects since these cardiovascular risk factors cluster with hyperglycemia.

30 August 2021 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
MRMatthew C Riddle
Matthew C Riddle
WCWilliam T Cefalu
William T Cefalu
PEPhilip H Evans
Philip H Evans
HGHertzel C Gerstein
Hertzel C Gerstein
MNMichael A Nauck
Michael A Nauck
DTDouglas Twenefour
Douglas Twenefour
Improvement of glucose levels into the normal range can occur in some people living with diabetes, either spontaneously or after medical interventions, and in some cases can persist after withdrawal of glucose-lowering pharmacotherapy. Such sustained improvement may now be occurring more often due to newer forms of treatment. However, terminology for describing this process and objective measures for defining it are not well established, and the long-term risks versus benefits of its attainment are not well understood. To update prior discussions of this issue, an international expert group was convened by the American Diabetes Association to propose nomenclature and principles for data collection and analysis, with the goal of establishing a base of information to support future clinical guidance. This group proposed “remission” as the most appropriate descriptive term, and HbA1c < 6.5% (48 mmol/mol) measured at least 3 months after cessation of glucose-lowering pharmacotherapy as the usual diagnostic criterion. The group also made suggestions for active observation of individuals experiencing a remission and discussed further questions and unmet needs regarding predictors and outcomes of remission.

20 February 2017 in BMJ Open Diabetes Research & Care
Verified
Journal Article
Open access
PDF file
ARAmy Rothberg
Amy Rothberg
LMLaura N McEwen
Laura N McEwen
AKAndrew T Kraftson
Andrew T Kraftson
NANevin Ajluni
Nevin Ajluni
CFChristine E Fowler
Christine E Fowler
WHWilliam H Herman
William H Herman
Objective: Central adiposity is a component of the metabolic syndrome (MetS). Little is known about the impact of medical weight loss and decreased waist circumference (WC) on the MetS. Our objective was to assess the impact of changes in WC on blood pressure, lipids and glycemia. Research design and methods: We studied 430 obese patients enrolled in a 2-year, intensive, behavioral, weight management program. We report results for participants who completed 6-month and 2-year follow-up. Results: Participants were 49±9 years of age (mean±SD), 56% were women and 85% were white. Baseline body mass index (BMI) was 41±6 kg/m2 and baseline WC was 120±14 cm. At 6 months, BMI decreased by 6±3 kg/m2 and WC by 14±9 cm. Relative change in WC was defined as the 6-month or 2-year WC minus the baseline WC divided by the baseline WC. Systolic blood pressure decreased by 8 mm Hg for the tertile of participants with the largest relative decrease in WC and by 2 mm Hg for those with the smallest relative decrease in WC (p=0.025). Similar patterns of improvement were observed in total cholesterol (−29 vs −12 mg/dL, p=0.017), low-density lipoprotein-cholesterol (−19 vs −4 mg/dL, p=0.033), and glycated hemoglobin (−1.2 vs −0.3%, p=0.006). At 2 years, BMI decreased by 5±4 kg/m2 and WC by 11±11 cm and similar patterns of improvements were seen in components of the MetS. At both 6 months and 2 years, larger relative decreases in WC were associated with greater improvements in lipids and glycemia independent of sex. Conclusions: In obese people, greater relative decreases in WC with medical weight loss are associated with greater improvements in components of the MetS independent of sex.

30 August 2021 in Diabetologia
Verified
Journal Article
Closed access
PDF file
MRMatthew C. Riddle
Matthew C. Riddle
WCWilliam T. Cefalu
William T. Cefalu
PEPhilip H. Evans
Philip H. Evans
HGHertzel C. Gerstein
Hertzel C. Gerstein
MNMichael A. Nauck
Michael A. Nauck
DTDouglas Twenefour
Douglas Twenefour

1 July 2014 in Journal of Diabetes and its Complications
Verified
Journal Article
Closed access
ARAmy Rothberg
Amy Rothberg
LMLaura N. McEwen
Laura N. McEwen
AKAndrew T. Kraftson
Andrew T. Kraftson
CFChristine E. Fowler
Christine E. Fowler
WHWilliam H. Herman
William H. Herman